ClinicalTrials.gg
Active, not recruitingNCT05551507Updated Nov 12, 2026

IN10018 in Combination With Standard Chemotherapy in High-grade Serous Epithelial Ovarian Cancer

A Phase 1/2 interventional study of IN10018 in combination with PLD in Platinum-resistant Ovarian Cancer, sponsored by InxMed (Shanghai) Co., Ltd.. Active, not recruiting at 7 sites in China. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-12.

Sponsored by InxMed (Shanghai) Co., Ltd. · Phase 1/2, Interventional, and Treatment

From the registry’s dates

  • Registered 2 years 1 month after the study started (first participant enrolled Jul 2020, registered Sep 2022).
Updated Nov 12, 2026Now Active, not recruitingPrimary completion moved+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
150
Allocation
Not applicable
Ages
18 Years and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 392 studies in Ovarian Neoplasms with a site in China — 198 open to participants now, 231 under way, 35 of them phase 3. Ovarian Neoplasms · China.

Planned enrollment
104th of 319
150 · median 83
Started
2020
with 26 others
Phase 1/2
53 of 392
32 open now
Primary completion
2026-05
later than 73 of 230 live
Registered
185th of 392
by date

Among the 392 studies in Ovarian Neoplasms with a site in China, this one is the 104th largest by planned enrollment of the 319 interventional ones that give a count, is one of 27 that started in 2020, is one of 53 in phase 1/2, reaches primary completion later than 73 of the 230 other live ones, and was the 185th registered.

Ovarian Neoplasms

3,387 studies on the registry are indexed under Ovarian Neoplasms; 791 are open to participants now.

Browse Ovarian Neoplasms studies →

Open to participants now

198 of the 392 studies in Ovarian Neoplasms with a site in China are open now. Recruiting first, the newest first:

193 more — sign in →

All 198 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 602 Ovarian Neoplasms studies recruiting now, 439 (73%) set no upper age limit and 107 (18%) stop at 75 or younger; 39 take children under 18; 45 take healthy volunteers.

This study: 18 Years and older · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 392 studies in Ovarian Neoplasms with a site in China, or all of them as a file.
02

Study summary

This is a phase Ib/II, open label clinical study to evaluate the safety, tolerability and antitumor activities of IN10018 in combination with standard chemotherapy in subjects with high-grade serous ovarian cancer (including fallopian tube cancer and primary peritoneum cancer, collectively defined as ovarian cancer).

Read the detailed description

Study will evaluate IN10018 in combination with pegylated liposomal doxorubicin (PLD) in subjects with platinum-resistant recurrent ovarian cancer. All the subjects will receive combination therapy until documented progressive disease or unacceptable toxicity.

03

Conditions studied

  • Platinum-resistant Ovarian Cancer

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Ability to understand and willingness to sign (s). Signed informed consent must be obtained before any study specific procedures, except those procedures used as institutional standard of care falling into the protocol specified window and fulfilling study specific requirements such as tumor imaging.
  2. Female subjects ≥ 18 years at the time of signing informed consent.
  3. confirmed epithelia ovarian cancer, fallopian tube cancer or primary peritoneum cancer with the subtype limited to high-grade serous carcinoma (HGSC) only.
  4. Subjects with platinum-resistant disease, defined as having or progressed between 1- 6 months after completion of prior platinum-based therapy (at least 4 cycles).
  5. Have maximum total of 5 and maximum 2 prior lines of systemic therapy following diagnosis of platinum-resistance.
  6. At least one can be accurately measured per 1.1 as assessed by investigator.
  7. performance status of 0 or 1.
  8. of at least 3 months as assessed by investigator.
  9. Availability of archival or fresh (newly obtained) tumor tissue sample during Screening Phase: Fresh tumor tissue sample obtained after most recent relapse or progression is preferred; if no sample or not sufficient number of slides can be provided or collected, a joint decision between Sponsor and investigator is needed for the enrollment of this subject.
  10. Must have recovered from all AEs due to previous therapies to ≤ Grade 1 ( 5.0) or stable status as assessed by investigator.
  11. Adequate bone marrow, liver, renal, and coagulation function within 5 days prior to first dose of study treatment.
  12. A female subject is eligible to participate if she is not pregnant, not breastfeeding, and at least 1 of the following conditions applies:

    • Not a woman of (WOCBP) . OR
    • A WOCBP who agrees to follow the guidance during the treatment period and through 3 months after the last dose of study treatment.

Exclusion criteria

Exclusion Criteria:

  1. Has had major surgery or significant traumatic injury within 28 days prior to first dose of study treatment, or diagnostic within 14 days prior to first dose of study treatment.
  2. Has received prior systemic anticancer therapy including agents, such as within 14 days or less than 5 half-lives (whichever is shorter) of chemotherapy or targeted therapy, or within 28 days of immunotherapy, prior to first dose of study treatment.
  3. Has received prior radiotherapy within 14 days prior to first dose of study treatment.
  4. Has received prior treatment of any FAK inhibitor or prior treatment of PLD.
  5. Has a known previous or concurrent cancer that is distinct in primary site or histology from current ovarian cancer within 3 years prior to first dose of study treatment, except for curatively treated cancers such as cervical carcinoma in situ.
  6. Has known active central nervous system (CNS) and/or carcinomatous meningitis.
  7. Has a history of major cardiovascular, cerebrovascular or thromboembolic diseases (e.g., congestive heart failure, acute myocardial infarction, unstable angina, stroke, , deep vein thrombosis or pulmonary embolism) within 6 months before first dose of study treatment, or has any of the following abnormality:

    • > 480 msec;
    • (LVEF) \< 50%;
    • (NYHA) functional classification ≥ Grade 2;
    • arrhythmia;
    • Uncontrolled hypertension;
    • Other clinically significant heart diseases.
  8. Has known uncontrollable pleural effusion, pericardial effusion, or ascites requiring repeated drainage. Note: A small amount of ascites that can only be detected by imaging examination is allowed.
  9. Has malabsorption syndrome or inability to take oral drugs.
  10. Has clinically significant gastrointestinal abnormalities including uncontrolled gastrointestinal inflammatory lesions (Crohn's disease, or ulcerative colitis in active) or uncontrolled gastrointestinal bleeding.
  11. Has an active infection requiring systemic therapy within 14 days prior to the first dose of study treatment.
  12. Has known (HIV) infection. Note: No HIV testing is required unless mandated by local health authority and/or site.
  13. Has known active or virus infection. Note: No testing for Hepatitis B and Hepatitis C is required unless mandated by local health authority and/or site.
  14. Has a history or current evidence of any condition, therapy, or laboratory abnormality that might confound the results of the study, interfere with the subject's participation for the full duration of the study, or is not in the best interest of the subject to participate, in the opinion of the treating investigator.
  15. Has a known psychiatric or substance abuse disorder that would interfere with the subject's ability to cooperate with the requirements of the study.
  16. Known allergy or to IN10018 or PLD, or their ingredients.
  17. Has received prior cumulative anthracycline dose of 550 mg/m2 or more.
  18. Has received systemic treatment of , CYP2D6 or P-gp strong inhibitors/inducers within 14 days prior to the first dose of study treatment, or anticipation of the systemic treatment of these drugs during Treatment Phase.
Terms in these criteria, in plain language(24)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
150 participants (estimated)

Study arms

  • Experimental
    IN10018 in combination with PLD

    IN10018 in combination with PLD in platinum-resistant recurrent epithelial ovarian cancer, fallopian tube cancer or primary peritoneum cancer with the subtype limited to high-grade serous carcinoma subjects.

    Drug: IN10018 in combination with PLD

Interventions

  • DrugIN10018 in combination with PLD

    Drug page: Ifebemtinib

    IN10018 in combination with PLD to treat subjects with platinum-resistant recurrent ovarian cancer

    Also known as: IN10018 add on to PLD treatment

06

What researchers measure

Primary outcomes

  1. Incidence of Treatment-Emergent Adverse Events per NCI-CTCAE version 5.0.

    Incidence of Treatment-Emergent Adverse Events per NCI-CTCAE version 5.0.

    Time frame: Up to 24 months

  2. Recommended phase 2 dose (RP2D) of the combination.

    Defined based on the incidence of dose limiting toxicities (DLTs).

    Time frame: Up to 2 months

  3. Objective response rate (ORR) as assessed by investigator.

    ORR is defined as the proportion of subjects with complete response (CR) and partial response (PR), as assessed by investigator per RECIST 1.1.

    Time frame: Up to 24 months

Secondary outcomes

  1. Objective response rate (ORR) as assessed by blinded independent central review (BICR).

    ORR is defined as the proportion of subjects with complete response (CR) and partial response (PR), as assessed by BICR per RECIST 1.1.

    Time frame: Up to 24 months

  2. Duration of response (DOR) as assessed by investigator and BICR.

    DOR is defined as the time from the first occurrence of objective response to disease progression or death from any cause (whichever occurs first), as assessed by investigator and BICR per RECIST 1.1.

    Time frame: Up to 24 months

  3. Disease control rate (DCR) as assessed by investigator and BICR.

    DCR is defined as the proportion of subjects with CR or PR, or stable disease, as assessed by investigator and BICR per RECIST 1.1.

    Time frame: Up to 24 months

  4. Progression free survival (PFS) as assessed by investigator and BICR.

    PFS is defined as the time from start of treatment to the first occurrence of disease progression or death from any cause (whichever occurs first), as assessed by investigator and BICR per RECIST 1.1.

    Time frame: Up to 24 months

  5. Overall survival (OS)

    OS is defined as the time from start of treatment to death from any cause.

    Time frame: Up to 24 months

  6. CA 125 response rate per Gynecological Cancer Inter-group (GCIG) criteria.

    CA 125 response rate per GCIG criteria.

    Time frame: Up to 24 months

07

Study locations

7 sites
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jul 2020 to primary completion in May 2026, 69 months.

Of 116 industry-sponsored phase 1/2 interventional studies under Ovarian Neoplasms, half reached primary completion within 61 months of starting (the median), counting those still running; a quarter within 44 and three quarters within 88. This study's 69 months is above that.

Counting every sponsor, half of 173 studies reached it within 65 months; a quarter within 44 and three quarters within 88.

Completion moved once since we started tracking on Sep 25, 2026: Sep 2026 → Dec 2026, on Nov 12, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Sep 15, 2022
First posted
Sep 22, 2022
StartActual
Jul 27, 2020
Primary completionActual
May 11, 2026
CompletionEst.
Dec 31, 2026was Sep 2026
Last update
Nov 12, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Recruiting→Active, not recruiting
changed Nov 12, 2026
Primary completion
May 31, 2026→May 11, 2026 (actual)
Nov 12, 2026
Study completion
Sep 30, 2026→Dec 31, 2026
Nov 12, 2026
Show all 1 update
  1. Nov 12, 2026
    Recruiting→Active, not recruiting
    Primary completion May 31, 2026→May 11, 2026 (now actual)
    Study completion Sep 30, 2026→Dec 31, 2026
    + 3 other changes: verification date, contact details and site details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT05551507
Lead sponsor
InxMed (Shanghai) Co., Ltd.
Responsible party
Sponsor
First posted
Sep 22, 2022
Start date
Jul 27, 2020
Primary completion
May 11, 2026
Completion
Dec 31, 2026 (estimated)
Last update
Nov 12, 2026

Study contacts

Lingying Wu
principal investigator · Cancer Hospital, Chinese Academy of Medical Science and Peking Union Medical College

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ifebemtinib

Start the discussion